SUNIKA - A non-interventional study with Sutent [sunitinib] in the first line treatment of renal cell carcinoma.
Phase of Trial: Phase IV
Latest Information Update: 15 Nov 2010
At a glance
- Drugs Sunitinib (Primary)
- Indications Renal cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms SUNIKA
- Sponsors Pfizer
- 03 Nov 2010 Primary endpoints added as reported by ClinicalTrials.gov.
- 10 Nov 2009 Actual patient number (356) added as reported by ClinicalTrials.gov.
- 10 Nov 2009 Actual end date (Sep 2009) added as reported by ClinicalTrials.gov.